Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice |
|
Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets |
|
Assessment of alteration in liver 18F-FDG uptake due to steatosis in lymphoma patients and its impact on the Deauville score. |
|
ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. |
|
Be ever cautious until the truth is proven |
|
The benefit of induction chemotherapy in patients age > or = 75 years |
|
Benefit of intravenous intermediate-dose methotrexate as prophylaxis in diffuse large B cell lymphoma at high risk of central nervous system relapse ?. |
|
Blood transfusion in hematologic intensive care unit. |
|
Caractérisation multiomique de la leucémie à tricholeucocytes et des proliférations lymphoïdes B avec cellules villeuses circulantes |
|
Characterization of drug resistance mechanisms in B cell hematologic diseases expressing cyclin D1 : impact of tumoral microenvironment. |
|
A combination of cytokines rescues highly purified leukemic CLL B-cells from spontaneous apoptosis in vitro |
|
Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment |
|
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. |
|
Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program |
|
Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy |
|
Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma. |
|
Does PET reconstruction method affect Deauville scoring in lymphoma patients? |
|
A French National Survey on Clotting Disorders in Mastocytosis |
|
Gastrointestinal manifestations in mastocytosis: a study of 83 patients. |
|
Harmonisation of full blood count reports, recommendations of the French-speaking cellular haematology group (GFHC). |
|
Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial |
|
Identification de BRD4 comme nouvelle cible thérapeutique dans le traitement des mastocytoses systémiques agressives (ASM) et des leucémies à mastocytes (MCL) |
|
Identification of Bromodomain-Containing Protein 4 (BRD4) as a Novel Marker and Epigenetic Target in Systemic Mastocytosis and Mast Cell Leukemia. |
|
Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: A retrospective single-center study |
|
Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases |
|
Intérêt d’une prophylaxie par Méthotrexate intra-veineux à dose intermédiaire dans le lymphome B diffus à grandes cellules à haut risque de rechute neuroméningée ? |
|
Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis |
|
Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. |
|
Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. |
|
Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive |
|
Mast cell sarcoma: new cases and literature review |
|
Mastocytosis among elderly patients: A multicenter retrospective French study on 53 patients |
|
Multiomic caracteization of hairy cell leukemia and villous B cells proliferations. |
|
New insights in the management of patients with hairy cell leukemia |
|
Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update |
|
Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma |
|
The prognostic value of hematogones in patients with acute myeloid leukemia |
|
R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. |
|
Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications |
|
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial |
|
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. |
|
Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program |
|
Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: a French nationwide study |
|
SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes |
|
T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells |
|
Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study |
|